Advanced search
Publication Cover
Journal of Medical Economics Volume 15, 2012 - Issue 6
Submit an article Journal homepage
683
Views
10
CrossRef citations to date
0
Altmetric
Original Article

Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing–remitting multiple sclerosis in The Netherlands

M. HeisenPharmerit Europe RotterdamThe NetherlandsCorrespondence[email protected]
,
M. J. TreurPharmerit Europe RotterdamThe Netherlands
,
W. S. van der HelNovartis Pharma B.V ArnhemThe Netherlands
,
S. T. F. M. FrequinMS Center Nieuwegein, Neurology, St. Antonius Hospital NieuwegeinThe Netherlands
,
M. T. GrootNovartis Pharma B.V ArnhemThe Netherlands
&
B. G. VerheggenPharmerit Europe RotterdamThe Netherlands
Pages 1149-1158 | Accepted 26 Jun 2012, Published online: 27 Jul 2012

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Mehdi Rezaee, Sadegh Izadi, Khosro Keshavarz, Afshin Borhanihaghighi & Ramin Ravangard. (2019) Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran. Journal of Medical Economics 22:4, pages 297-305.
Read now
Olivier Outteryck. (2016) Natalizumab in relapsing-remitting multiple sclerosis. Expert Review of Neurotherapeutics 16:5, pages 471-481.
Read now
Radu Tanasescu & Cris S Constantinescu. (2014) Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis. Expert Opinion on Drug Metabolism & Toxicology 10:4, pages 621-630.
Read now

Articles from other publishers (7)

Anggie Wiyani, Lohit Badgujar, Vivek Khurana & Nicholas Adlard. (2021) How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review. Neurology and Therapy 10:2, pages 557-583.
Crossref
Anna Mokrova, Susanna Sologova & Victoria Ignatyeva. (2020) Modelling expenses for multiple sclerosis treatment. Farmacevticheskoe delo i tehnologija lekarstv (Pharmacy and Pharmaceutical Technology):3, pages 11-34.
Crossref
Matteo Ruggeri, Andrea Aiello, Anna D'Ausilio, Eugenio Di Brino, Salvatore Cottone, Angelo Ghezzi, Lorella Lombardozzi, Alessandra Mecozzi, Dario Sacchini, Alessandro Roccia, Monica Mangone & Mondher Toumi. (2016) Evolution of the Healthcare Expenditure in Italy and Effects of Fingolimod Increased Prescribing in Second Line Treatment of Relapsing-Remitting Multiple Sclerosis. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 3:3, pages GRHTA.5000232.
Crossref
Siddharama Pawate & Francesca Bagnato. (2015) Newer Agents in the Treatment of Multiple Sclerosis. The Neurologist 19:4, pages 104-117.
Crossref
Mark Sanford. (2014) Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple Sclerosis. Drugs 74:12, pages 1411-1433.
Crossref
C. Crespo, G. Izquierdo, A. García-Ruiz, M. Granell & M. Brosa. (2014) Cost minimisation analysis of fingolimod vs. natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis. Neurología (English Edition) 29:4, pages 210-217.
Crossref
C. Crespo, G. Izquierdo, A. García-Ruiz, M. Granell & M. Brosa. (2014) Análisis de minimización de costes entre fingolimod y natalizumab en segunda línea de tratamiento de esclerosis múltiple remitente-recurrente. Neurología 29:4, pages 210-217.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.